Postprandial C-peptide to glucose ratio as a predictor of β-cell function and its usefulness for staged management of type 2 diabetes

Journal of Diabetes Investigation

Volumn 5, Issue 5, 2014, Pages 517-524

  Lee, Eun Young ^a   Hwang, Sena ^a,b   Lee, Seo Hee ^a   Lee, Yong Ho ^a   Choi, A Ra ^a   Lee, Youngki ^a   Lee, Byung Wan ^a   Kang, Eun Seok ^a   Ahn, Chul Woo ^a   Cha, Bong Soo ^a   Lee, Hyun Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

C peptide; Pancreatic cell; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DISEASE DURATION; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC INDEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; KOREAN (PEOPLE); LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PREDICTION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 84908575350     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12187     Document Type: Article

References (29)

1. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13(Suppl 1): 1-68.
2. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(Suppl 1): S11-S63.
3. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011; 17(Suppl 2): 1-53.
4. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3-19.
5. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40(Suppl): S21-S25.
6. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
7. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
8. Levy J, Atkinson AB, Bell PM, et al. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-296.
9. Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM 2003; 96: 281-288.
10. Tsai EB, Sherry NA, Palmer JP, et al. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia 2006; 49: 261-270.
11. Meier J, Menge BA, Breuer TG, et al. Functional assessment of pancreatic beta-cell area in humans. Diabetes 2009; 58: 1595-1603.
12. Lee SH, Lee B-W, Won HK, et al. Postprandial triglyceride is associated with fasting triglyceride and HOMA-IR in Korean subjects with type 2 diabetes. Diabetes Metab J 2011; 35: 404-410.
13. Dixon JR. The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur 1998; 6: 65-74.
14. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003; 52: 1210-1214.
15. Rudenski AS, Hadden DR, Atkinson AB, et al. Natural history of pancreatic islet B-cell function in type 2 diabetes mellitus studied over six years by homeostasis model assessment. Diabet Med 1988; 5: 36-41.
16. Ostgren CJ, Lindblad U, Ranstam J, et al. Glycaemic control, disease duration and beta-cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project. Diabet Med 2002; 19: 125-129.
17. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.
18. Rhee SY, Woo J-T. The prediabetic period: review of clinical aspects. Diabetes Metab J 2011; 35: 107-116.
19. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
21. Albarrak AI, Luzio SD, Chassin LJ, et al. Associations of glucose control with insulin sensitivity and pancreatic beta-cell responsiveness in newly presenting type 2 diabetes. J Clin Endocrinol Metab 2002; 87: 198-203.
22. Shim WS, Kim SK, Kim HJ, et al. Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes. Eur J Endocrinol 2006; 155: 615-622.
23. Funakoshi S, Fujimoto S, Hamasaki A, et al. Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. J Diabetes Invest 2011; 2: 297-303.
24. Goto A, Takaichi M, Kishimoto M, et al. Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J 2010; 57: 237-244.
25. Saisho Y, Kou K, Tanaka K, et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 2011; 58: 315-322.
26. Saisho Y, Kou K, Tanaka K, et al. Postprandial serum C-peptide to plasma glucose ratio predicts future insulin therapy in Japanese patients with type 2 diabetes. Acta Diabetol 2012; doi:10.1007/s00592-012-0441-y.
27. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
28. Gjessing HJ, Damsgaard EM, Matzen LE, et al. Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus. Diabetes Care 1987; 10: 558-562.
29. Scheen AJ, Castillo MJ, Lefèbvre PJ. Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 1996; 22: 397-406.